Ocrelizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase III drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ocrelizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ocrelizumab overview
Ocrelizumab (Ocrevus) is a humanized monoclonal antibody. It is formulated as concentrated solution and solution for intravenous route of administration. Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease, as a monotherapy for the management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity.
It is under development for the treatment of autoimmune encephalitis, primary progressive multiple sclerosis, relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis and relapsing multiple sclerosis. It was also under development for rheumatoid arthritis, systemic lupus erythematosus, follicular non-Hodgkin's lymphoma and lupus nephritis. It is administered through subcutaneous route.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Ocrelizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
